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Abstract
Objective—Little is known about the long-term costs of lupus nephritis (LN). These were 
compared between patients with and without LN based on multistate modelling.
Methods—Patients from 32 centres in 11 countries were enrolled in the Systemic Lupus 
International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis and 
provided annual data on renal function, hospitalizations, medications, dialysis, and selected 
procedures. LN was diagnosed by renal biopsy or the American College of Rheumatology 
classification criteria. Renal function was assessed annually using estimated glomerular filtration 
rate (eGFR) or proteinuria (ePrU). A multistate model was used to predict 10-year cumulative 
costs by multiplying annual costs associated with each renal state by the expected state duration.
Results—1,545 patients participated, 89.3% female, mean age at diagnosis 35.2 years (SD 13.4), 
49.0% Caucasian, and mean follow up 6.3 years (SD 3.3). LN developed in 39.4% by the end of 
follow up. Ten-year cumulative costs were greater in those with LN and an eGFR < 30 ml/min 
($310 579 2015 Canadian dollars versus $19 987 if no LN and eGFR > 60 ml/min) or with LN and 
ePrU > 3 g/d ($84 040 versus $20 499 if no LN and ePrU < 0.25 g/d).
Conclusion—Patients with eGFR < 30 ml/min incurred 10-year costs 15-fold higher than those 
with normal eGFR. By estimating the expected duration in each renal state and incorporating 
associated annual costs, disease severity at presentation can be used to anticipate future healthcare 
costs. This is critical knowledge for cost-effectiveness evaluations of novel therapies.
Introduction
Renal disease in SLE patients is associated with significant morbidity and mortality, and is 
extremely costly (1). Approximately 40% of SLE patients develop lupus nephritis (LN), 
although in African descendants and Hispanics of predominantly Amerindian ancestry the 
frequency may be as high as 60% (2–4). Lupus nephritis varies from clinically silent 
pathology to end-stage renal disease (ESRD), and is often present at the time of SLE 
diagnosis (2). The current standard of care includes induction with corticosteroids and 
mycophenolate mofetil, cyclophosphamide, or rituximab and long-term maintenance therapy 
with mycophenolate mofetil or azathioprine (5,6). Despite receiving treatment according to 
established guidelines, a significant proportion of patients still progress to ESRD, requiring 
dialysis or transplantation. Recent studies including a 30-year single centre study (7) 
indicate that the 5-year risk of ESRD in SLE patients with renal disease ranges between 
6.9% to 8.1% and a meta-analysis (8) reports that the 5-year risk of ESRD in those with LN 
decreased from 16% in the 1970s to 11% in the mid-1990s. These rates have plateaued for at 
least the past two decades. The presence of renal damage is the most important predictor of 
early mortality in SLE patients (9); in fact, it has been shown that renal damage reduces the 
survival of SLE patients by approximately 24 years, compared to the general population (10) 
and LN patients who develop ESRD have a 26-fold increased risk of mortality (11). Hence, 
numerous studies demonstrate significantly higher costs in patients with LN versus those 
without LN (1,12–14).
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While SLE patients with renal injury are known to have increased healthcare costs compared 
to those without renal involvement (15), there is very little data on the long-term healthcare 
costs of LN patients (12). Between 1999 and 2011, the Systemic Lupus International 
Collaborating Clinics (SLICC) enrolled patients into an inception cohort to study long-term 
clinical outcomes. In previous research on this cohort, reversible multistate modeling has 
been used to estimate transitions (improvement or deterioration) between multiple states of 
renal function (16). This type of modeling is unique in that it provides a dynamic 
representation of renal dysfunction in continuous time as opposed to the typical static cross-
sectional view provided by conventional regression analyses. In the current study, multistate 
modeling was used to forecast the duration in each renal state and the annual direct costs 
associated with each renal state were calculated. Five and ten-year cumulative costs were 
then estimated by multiplying the annual costs associated with each renal state with the 
expected duration in that state and were compared between patients with and without renal 
involvement. This methodology allows for prediction of costs for renal states in which there 
are few observations.
Understanding how patients progress through states of renal disease and the costs associated 
with each state will allow for cost-effectiveness analyses of novel emerging therapies.
Patients and Methods
Inception cohort
The SLICC network includes 32 academic centres from 11 countries (17). Members of this 
network enrolled patients fulfilling the American College of Rheumatology (ACR) revised 
classification criteria for SLE (18) into an inception cohort within 15 months of SLE 
diagnosis (i.e., date at which criteria were met). For this study, data collection extended from 
1999 through to 2013. Data were collected at enrollment on demographics (age, sex, race/
ethnicity) and at enrollment and annually (± 6 months) on disease activity [SLE Disease 
Activity Index – 2000 (SLEDAI-2K) (19)], disease damage [SLICC/ACR Damage Index 
(SDI) (20)], smoking history, and alcohol consumption [high risk consumption defined as 
greater than 10 units per week for females and 15 units per week for males (21)]. Data were 
also collected annually on all hospitalizations, medications (including corticosteroids, 
antimalarials, immunosuppressives, biologics, antihypertensives, lipid-lowering agents, anti-
epileptics, anti-psychotics and other psychoactive drugs, anticoagulants, and antiplatelets), 
and dialysis from any time since the previous assessment. The initial focus of the inception 
cohort was on cardiovascular and neuropsychiatric outcomes and later, on renal outcomes, 
and as part of the data collection protocol, diagnostic procedures related only to these 
outcomes were also recorded (e.g. ECGs, echocardiograms, stress tests, neuroimaging, and 
renal biopsies) and used for resource use and cost estimation. The study was approved by the 
institutional research ethics review board at each site and each participant provided written 
informed consent.
Renal status
Lupus nephritis was diagnosed by renal biopsy or fulfillment of the renal item on the ACR 
classification criteria for SLE (18).
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Renal function was also assessed annually based on estimated glomerular filtration rate 
(eGFR) using the Modification of Diet in Renal Disease (MDRD) equation (22), or on 
estimated proteinuria (ePrU) as measured by either 24 hour urine collection or spot urine 
total protein to creatinine ratio (23). eGFR was divided into three states: state 1 (eGFR > 60 
ml/min), state 2 (eGFR 30-60 ml/min) and state 3 (eGFR < 30 ml/min). ePrU was stratified 
as: state 1 (ePrU < 0.25 g/d), state 2 (ePrU 0.25-3 g/d), or state 3 (ePrU > 3g/d). End stage 
renal disease (ESRD) was identified based on the SDI renal variable (20).
Statistical Analysis
Multistate Modelling—At each assessment, patients were assessed for the presence of LN 
and state of eGFR and ePrU and were assigned to one of six states in Markov models 
(Figure 1) for either eGFR or ePrU. Within the eGFR model, it was clinically sensible to 
assume that a patient could not move from an eGFR state 1 or 2 to ESRD without first 
having transitioned through eGFR state 3 with LN. However, within the ePrU model, it was 
clinically reasonable to assume that a patient could develop ESRD from any ePrU state with 
LN. Further, in both models, direct transition from one state to a non-adjacent state was not 
permitted in continuous time (except for transition of ePrU state 1 or state 2 with LN to 
ESRD) and transitions could occur into adjacent higher or lower states, except for ESRD or 
LN where the transitions were unidirectional. However, changes between non-adjacent states 
could be observed between assessments, with the transition being assumed to occur through 
a set of adjacent transitions. Death was regarded as a censoring event consistent with the 
collection of cost data only in years when death did not occur.
Due to small numbers of transitions into less frequent states, the transition rates between 
observed states were estimated with a null multistate model without explanatory variables 
[full details provided in (16)]. This model can account for intermittent observations and, 
through conditioning on current states, for the correlation between observations within the 
same patient. The correlation among the states of a patient at the different assessment visits 
was characterized through the Markov assumption that the future evolution of a patient’s 
renal function depends only on his/her current state and not on his/her previous history. 
Transition rates were estimated through maximum likelihood estimation and expected state 
occupancy times over fixed follow-up periods were also obtained.
Calculating costs—Costs included all hospitalizations, medications, dialysis, and 
diagnostic procedures related to cardiovascular, neuropsychiatric, and renal manifestations. 
Costs were calculated from the Canadian national health insurance perspective by 
multiplying each health resource by its corresponding Canadian unit cost at the 2015 price 
level. Except for hospitalizations, national estimates for unit costs were based on provincial 
price data from the Ontario and Quebec Ministries of Health, adjusted to reflect average 
Canadian prices. The unit cost for medications was sourced from the Quebec List of 
Medications (published by the Régie de l'assurance maladie du Québec). Reimbursement for 
physician services related to investigations, dialysis and other procedures was based on the 
Ontario fee schedule (published by the Ontario Health Insurance Plan), and hospital costs 
for dialysis and day procedures were sourced from the Ontario Case Costing Initiative 
(OCCI) (24). Costs for hospitalizations were developed through the Case-Mix Group 
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method from the Canadian Institute for Health Information (CIHI). This methodology 
adjusts for the case complexity through resource intensity weights. Appropriate weights 
were identified using data from previous research on reasons for hospitalizations in a 
representative sample of lupus patients (25). Cost per in-patient day was derived from this 
data, which also incorporated physician reimbursements during hospital stays, based on fee 
schedules from Ontario and Quebec. Adjustment to average Canadian 2015 price levels was 
done, in the case of medications, using the Consumer Price Index (http://www.statcan.gc.ca/
tables-tableaux/sum-som/l01/cst01/econ09a-eng.htm) ratio of provincial to national price 
indices for prescribed medicines, and for all other health services, using similar wage ratios 
for labour in the healthcare sector across provinces and calendar years (http://
www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health23-eng.htm).
To compute estimates of 5 and 10-year cumulative costs, annual costs associated with each 
state of renal function, defined as presence of LN and state of eGFR or ePrU or ESRD, were 
first estimated. Generalized least squares regression modeling with random effects was used 
to account for possible confounding of the relationship between annual costs and state of 
renal function. Potential confounding covariates included age, sex, race/ethnicity, geographic 
region (i.e. within versus outside of North America), disease duration, smoking, and high-
risk alcohol use. Adjusted annual cost estimates were predicted using the average values of 
relevant confounders, and confidence intervals (CI) were calculated using the bootstrapping 
method, accounting for the non-normal distribution of healthcare costs. Five and ten-year 
cumulative costs stratified by baseline renal state were calculated by multiplying the 
adjusted annual cost estimates associated with each renal state by the expected duration in 
each state over five and ten years. However, accurate discounting of future costs required 
this calculation to be done for each consecutive year, using expected duration over one-year 
and repeating the process for longer term estimates. The year-to-year change in state was 
approximated using transition probabilities estimated after one year. The one-year state 
durations and transition probabilities were both derived from multistate modelling (16). 
Future annual costs for each baseline renal state were discounted at a yearly rate of 3% and 
annual costs were summed over the five-or-ten year period. Note that since the null 
multistate model does not include adjustment variables, predicted long-term costs can be 
compared based on this model, but will only reflect partial adjustment for confounders.
Results
Patients
A total of 1826 patients were recruited from 32 SLICC centres in 11 countries. Of these, 
1545 patients (United States, n= 426; Europe, n=405; Canada, n=372; Mexico, n=184; and 
Korea, n=158) (Table 1) had at least an enrollment and one follow up assessment, allowing 
for costing analysis, and were therefore included in the analysis. Patients were 89.3% 
female, with a mean age at diagnosis of 35.2 years (SD 13.4), mean disease duration at 
enrollment of 0.47 years (SD 0.35), and mean follow up of 6.3 years (SD 3.3) (range: 0.6 to 
13.7 years); 49.0% of the patients were Caucasian. These characteristics are similar to those 
for the entire cohort (2).
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Renal status
Lupus nephritis was diagnosed in 609/1545 patients (39.4%). It was present at enrollment in 
466/1545 patients (30.2%) and developed during follow up in another 143/1545 patients 
(9.3%).
Annual costs and predictors
For the eGFR model examining the association between annual costs and state of renal 
function, age greater than 65 years [regression coefficient $1700 (95% CI $8, $3392)] and 
region outside of North America [regression coefficient $1183 (95% CI $409, $1956)] were 
associated with higher annual costs and Caucasian race/ethnicity [regression coefficient - 
$870 (95% CI -$1653, -$88)] was associated with lower costs. For the ePrU model, the same 
variables were associated with annual costs [age > 65 years: regression coefficient $2229 
(95% CI $601, $3858), region outside of North America regression coefficient $1110 (95% 
CI $337, $1884) and Caucasian race/ethnicity regression coefficient -$789 (95% CI - $1573, 
$-4)].
Once adjusted accordingly, i.e., calculated at cohort average values (in this case, the 
observed proportions of patients older than 65 years, residing outside of North America, and 
of Caucasian race/ethnicity in the sample), annual costs by renal state were markedly higher 
in those with ESRD than in those without LN and eGFR > 60 ml/min (state 1, no LN) or 
ePrU < 0.25 g/d (state 1, no LN) [($51 313 (95% CI $38 645, $63 982) versus $1813 (95% 
CI $1034, $2593) versus $1797 (95% CI $995, $2599)] (Table 2).
Annual unadjusted component costs are provided in Supplementary Table 1. In patients 
without LN, medications were the most costly component, whereas in those patients with 
LN and eGFR < 30 ml/min or with ESRD, dialysis was the most costly component. In 
patients with ePrU 0.25 g/d or more, with or without LN, hospitalization was the most costly 
component. In all other renal states, medications were the most costly component.
Transition probabilities and expected state durations
Based on the estimated transition rates between states, the probability and expected duration 
for each state of eGFR and ePrU in the absence and presence of LN after 1 year is shown in 
Table 3. As anticipated, for example, patients with LN and a baseline eGFR > 60 ml/min 
(state 1, LN) had a much lower probability of transitioning to ESRD (0.1%) than those with 
LN and a baseline eGFR < 30 ml/min (state 3, LN) (37.6%). Accordingly, patients with LN 
and an eGFR > 60 mL/min (state 1, LN) were forecasted to spend none of the next year in 
ESRD, whereas patients with LN and an eGFR <30 mL/min (state 3, LN) were forecasted to 
spend one fifth of the next year in ESRD (Table 3). Transition probabilities after 1 year and 
expected state durations over 1 year are also shown for ePrU in Table 3.
Five and ten-year cumulative costs
Five-year cumulative costs were predicted to be substantially higher in patients with LN and 
an eGFR < 30 mL/min (state 3, LN) or with ESRD at baseline (Table 4). Patients with LN 
and an eGFR < 30 mL/min (state 3, LN) had 5-year cumulative costs of $154 320 (95% CI 
$100 919, $207 721) and those with ESRD had costs of $242 196 (95% CI $182 407, $301 
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985) while those without LN and eGFR > 60 mL/min (state 1, no LN) at baseline were 
expected to accrue 5-year cumulative costs of $9536 (95% CI $5246, $13 825) (Table 4).
Ten-year cumulative costs were also greater in those with LN and an eGFR < 30 mL/min 
(state 3, LN) or with ESRD at baseline. Patients with LN and an eGFR < 30 mL/min (state 
3, LN) had 10-year cumulative costs of $310 579 (95% CI $217 631, $403 528) and those 
with ESRD had costs of $451 406 (95% CI $339 977, $562 835) while those without LN 
and eGFR > 60 mL/min (state 1, no LN) at baseline had 10-year cumulative costs of only 
$19 987 (95%CI $11 061, $28 913) (Table 4).
Similarly, when renal function was stratified by ePrU, five-year cumulative costs were 
highest in those with LN and an ePrU of >3 g/d (state 3, LN) or with ESRD at baseline. 
Patients with LN and an ePrU of > 3g/d (state 3, LN) had 5-year cumulative costs of $39 638 
(95% C1 $27 834, $51 441) while those without LN and ePrU of <0.25 g/d (state 1, no LN) 
at baseline had 5-year cumulative costs of only $9651 (95% CI $5393, 13 909) (Table 4). 
Ten-year cumulative costs were also greater in those with LN and an ePrU of > 3 g/d (state 
3, LN) or with ESRD at baseline (Table 4).
Discussion
We have provided the first comparison of annual and 5 and 10-year cumulative costs 
stratified by baseline renal function in an international, multi-ethnic inception cohort of SLE 
patients. The use of an inception cohort allows for the development of multistate modeling, 
which can be used to forecast expected duration in each renal state. By incorporating annual 
costs associated with each renal state, long-term cumulative costs can be estimated stratified 
by baseline renal status. The regression model examining the association between annual 
costs and state of renal function produced point estimates of higher annual costs by an 
average of $870 in non-Caucasians compared to Caucasians in the eGFR model and an 
average of $789 in the ePrU model, consistent with literature on poorer health outcomes in 
non-Caucasians (26). As anticipated, worsening renal disease resulted in higher healthcare 
costs, with patients with ESRD projected to incur 10-year cumulative costs almost 23-fold 
that of patients with no LN and normal eGFR [($451 406 (95% CI $339 977, $562 835) 
versus $19 987 (95% CI $11 061, $28 913)]. Even patients with LN with eGFR < 60 ml/min 
who did not have ESRD still incurred substantial costs [($111 326 (95% CI $76 466, $146 
185) to $310 579 (95% CI $217 631, $403 528)]. Patients with an eGFR < 30 ml/min and 
LN are substantially more expensive than patients with ePrU > 3 g/L and LN (10-year costs 
of $310 579 versus $84 040), because the former represent a sicker group of patients.
However, our study has some limitations. The SLICC network is based within tertiary care 
academic centres and therefore our patient population may not represent the entire spectrum 
of SLE patients and likely overestimates the hospitalization, medication, and dialysis costs 
incurred by SLE patients in a community practice. Further, we did not capture indirect costs 
due to lost productivity in paid and unpaid endeavors. Additionally, our assessment of 
healthcare resource utilization was incomplete and therefore we have underestimated total 
direct costs. While we did capture the most costly components of health resource use – 
hospitalizations, medications, dialysis, and physician visits associated with these services, 
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we did not collect data on other physician or emergency room visits and our assessment of 
diagnostic procedures was restricted to those related to cardiovascular, neuropsychiatric, and 
renal disease. Based on our previous work (27) estimating long-term costs for Canadian 
lupus patients, where all components of direct costs were included, our current estimates 
would represent, on average, 68% of total direct costs. Our costs were also based only on 
data that was recorded while patients survived and incurred costs for the whole period 
preceding questionnaire administration. There were 36 deaths in the study (Supplemental 
Table 2) and because of our study design, we have no data on resource use in the year 
preceding death.
The substantial cost of LN has been reported by others, primarily through the use of 
insurance claims databases. Studies from the US have shown that patients with LN incurred 
annual costs that are 2.5 to 6-fold higher than patients without LN (1,12–14). Carls et al. 
reported annual costs were almost 4-fold higher in US patients with LN [$83 869 versus 
$ 22 188 in those without LN]1 (1) while Furst et al. reported that patients with LN incurred 
annual costs of $44 524 versus $7113 in matched controls without SLE (14). A Medicaid 
study reported lower annual costs, but the differential between those with LN and matched 
controls without SLE was almost 3-fold [$38 401 versus $12 945] (12). These annual costs 
for patients with LN are substantially higher than our estimates, which range between $3858 
and $20 837 depending on the eGFR. However, our cost estimates for ESRD of $ 51 313 are 
more comparable to the estimates for LN based on insurance data. It is to be expected that 
our estimates are lower as we did not include all healthcare resources and we used Canadian 
prices for healthcare, which are much lower than in the US, relative to other consumer 
goods.
However, use of insurance claims data is limited by reliance on diagnostic codes, which may 
lead to inclusion of patients who do not have LN, and the lack of detailed data on renal 
pathology and renal function. Other studies have employed self-reported healthcare 
utilization in a clinical cohort to estimate the direct costs associated with LN (15), 
demonstrating almost 5-fold higher costs in ESRD patients compared to SLE patients 
without any renal damage as defined on the SDI ($144 389 versus $29 499). In our current 
study, we observed an over 25-fold difference in 5-year costs between those with ESRD and 
an eGFR > 60 ml/min and no LN ($242 196 versus $9536). This much higher differential in 
our current study is attributable to two factors: 1) the costs of ESRD are higher in the current 
study because they are more precise and 2) the costs incurred by patients without renal 
damage as defined by the SDI are higher than in our current study because these patients 
were older, had accrued more non-renal damage, and also had renal dysfunction not 
sufficient to fulfill the SDI renal criteria.
A recent Swedish study estimated both the annual direct and indirect costs of LN compared 
to all SLE patients by linking well-defined clinical cohorts to national registries and the 
social insurance system. SLE patients with LN incurred direct costs of $18 579 compared to 
1Currencies from publications have been converted to 2015 Canadian dollars using purchasing power parities data from the 
Organisation for Economic Cooperation and Development (https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm) and 
the consumer price index from Statistics Canada (http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ09a-eng.htm).
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$13 339 in all SLE patients (28), with indirect costs comprising approximately 60% of total 
costs for those with LN and 70% for those without LN. These direct cost estimates for 
patients with LN are reasonably comparable to ours where annual costs ranged between 
$3858 and $20 837 for those with LN, but without ESRD.
Unfortunately, the frequency and survival of SLE-related ESRD has not improved over 
several decades (7,8,29,30), highlighting the need for new therapies. Although numerous 
clinical trials of biologics have yielded disappointing results for LN, novel agents continue 
to emerge, and there is optimism that some will be proven effective (31). Koutsokeras and 
Healy (32,33) forecasted the LN market to be $505 million by 2022 for seven major 
international markets (United States, France, Germany, Italy, Spain, the United Kingdom, 
and Japan). As novel biologics become available, understanding the current costs of LN 
using standard of care is necessary for cost-effectiveness studies. Biologics are very costly, 
and are often utilized for only refractory or advanced disease. However, they are likely to 
become more cost-effective over time as their patents expire while the cost of dialysis is 
unlikely to decrease. Our study demonstrates the substantial cost increases in patients with 
more advanced renal disease, highlighting the cost savings potentially achieved by earlier 
aggressive therapy to prevent progression or induce remission of renal disease.
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Significance and Innovations
• We are providing the first estimates of annual and 5 and 10-year cumulative 
costs stratified by baseline renal function in an international, multi-ethnic 
inception SLE cohort.
• An inception cohort allows for the development of multistate modeling, which 
provides a dynamic representation of both improvement and deterioration of 
renal disease in continuous time.
• Patients with lupus nephritis and a baseline eGFR < 30 ml/min incurred ten-
year costs of $310 579 (2015 Canadian dollars) versus $19 987 if they did not 
have lupus nephritis and their baseline eGFR was > 60 ml/min.
• Similarly, patients with lupus nephritis and a baseline ePrU > 3 g/d incurred 
ten-year costs of $84 040 (2015 Canadian dollars) versus $20 499 if they did 
not have lupus nephritis and their baseline ePrU was <0.25 g/d.
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Figure 1. Multstate Markov model for observed transitions between estimated glomerular 
filtration rate (eGFR) and estimated proteinuria (ePrU) states
eGFR: state 1 > 60 mL/min, state 2 30 – 60 mL/min, state 3 < 30 mL/min
ePrU: state 1 < 0.25 g/d, state 2 0.25 – 3.0 g/d, state 3 > 3.0 g/d
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Table 1
Baseline demographic and clinical manifestations of patients
No. of patients: 1545
Age (years): (Mean ± SD) 35.2 (13.4)
Gender (%):
                Female 89.3
                Male 10.7
Race/Ethnicity (%):
                Caucasian 49.0
                Hispanic 14.9
                Asian 16.1
                African 16.2
                Other 3.8
Country (%):
                United States 27.6
                Europe 26.2
                Canada 24.1
                Mexico 11.9
                Korea 10.2
Disease Duration (yr) (Mean ± SD) 0.47 (0.35)
ACR Classification Criteria (%):
                Malar Rash 34.7
                Discoid Rash 11.4
                Photosensitivity 34.4
                Oral/nasopharyngeal Ulcers 36.1
                Serositis 27.1
                Arthritis 72.4
                Renal Disorder 26.9
                Neurological Disorder 4.9
                Hematologic Disorder 61.1
                Immunologic Disorder 73.4
                Antinuclear Antibody 92.0
SLEDAI-2K (Mean ± SD) 5.3 (5.3)
SDI score (Mean ± SD) * 0.32 (0.73)
Medications (%):
                Corticosteroids 70.3
                Antimalarials 67.3
                Immunosuppressants 39.0
Comorbidities/Lifestyle
                Current Smoker (%) 14.7
                Alcohol (% with high risk consumption) 1.2
ACR = American College of Rheumatology; SDI = SLICC/ACR Damage index; SLEDAI-2K = SLE Disease Activity Index – 2000
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*
For patients with a disease duration of less than six months, SDI cannot be calculated – therefore at enrolment, SDI was available on 580 patients
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2019 March 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Barber et al. Page 18
Table 2
Predicted annual health costs stratified by state of eGFR and ePrU
eGFR ePrU
eGFR/ePrU State*
Costs, 2015 CDN$
(Mean, 95% CI)
Costs, 2015 CDN$
(Mean, 95% CI)
State 1 (no LN) 1813 (1034, 2593) 1797 (995, 2599)
State 2/3 (no LN) 2955 (37, 5873) 2740 (1467, 4013)
State 1 (LN) 3858 (2858, 4859) 3768 (2341, 5194)
State 2 (LN) 4012 (2362, 5662) 4739 (3485, 5993)
State 3 (LN) 20837 (3628, 38046) 5643 (3302, 7984)
ESRD 51313 (38645, 63982) 50944 (38158, 63730)
eGFR = estimated glomerular filtration rate; ePrU = estimated proteinuria; ESRD = end-stage renal disease; LN = lupus nephritis; CDN = 
Canadian
*
eGFR: state 1 > 60 mL/min, state 2 30 – 60 mL/min, state 3 < 30 mL/min
ePrU: state 1 < 0.25 g/d, state 2 0.25 – 3.0 g/d, state 3 > 3.0 g/d
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2019 March 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Barber et al. Page 19
Table 3
Probabilities of transitioning between states and duration of eGFR and ePrU states over 1 
year
Initial State*
Probability of being in state after 1 year
State 1
no LN
State 2/3
no LN
State 1
LN
State 2
LN
State 3
LN ESRD
eGFR
     State 1 (no LN) 0.955 0.020 0.024 0.001 0.000 0.000
     State 2/3 (no LN) 0.364 0.598 0.011 0.025 0.002 0.000
     State 1 (LN) 0 0 0.957 0.039 0.003 0.001
     State 2 (LN) 0 0 0.314 0.557 0.096 0.033
     State 3 (LN) 0 0 0.040 0.146 0.438 0.376
     ESRD 0 0 0 0 0 1
ePrU
     State 1 (no LN) 0.931 0.050 0.012 0.006 0.001 0.000
     State 2/3 (no LN) 0.674 0.216 0.028 0.065 0.015 0.002
     State 1 (LN) 0 0 0.814 0.171 0.011 0.004
     State 2 (LN) 0 0 0.354 0.567 0.063 0.016
     State 3 (LN) 0 0 0.162 0.467 0.314 0.057
     ESRD 0 0 0 0 0 1
Expected duration in state over 1 year
eGFR
     State 1 (no LN) 0.977 0.011 0.012 0.000 0.000 0.000
     State 2/3 (no LN) 0.198 0.781 0.004 0.015 0.001 0.000
     State 1 (LN) 0 0 0.977 0.022 0.001 0.000
     State 2 (LN) 0 0 0.173 0.752 0.062 0.012
     State 3 (LN) 0 0 0.014 0.093 0.684 0.209
     ESRD 0 0 0 0 0 1
ePrU
     State 1 (no LN) 0.960 0.032 0.006 0.002 0.000 0.000
     State 2/3 (no LN) 0.434 0.499 0.011 0.044 0.010 0.001
     State 1 (LN) 0 0 0.895 0.100 0.004 0.001
     State 2 (LN) 0 0 0.206 0.743 0.043 0.008
     State 3 (LN) 0 0 0.065 0.323 0.580 0.032
     ESRD 0 0 0 0 0 1
eGFR = estimated glomerular filtration rate; ePrU = estimated proteinuria; ESRD = end-stage renal disease; LN = lupus nephritis;
*
eGFR: state 1 > 60 mL/min, state 2 30 – 60 mL/min, state 3 < 30 mL/min
ePrU: state 1 < 0.25 g/d, state 2 0.25 – 3.0 g/d, state 3 > 3.0 g/d
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Table 4
Predicted 5-year and 10-year cumulative health costs stratified by baseline state of renal 
function for eGFR and ePrU
eGFR/ePrU State*
eGFR
Costs, 2015 CDN$
(Mean, 95% CI)
ePrU
Costs, 2015 CDN$
(Mean, 95% CI)
5-year
     State 1 (no LN) 9536 (5246, 13825) 9651 (5393, 13909)
     State 2/3 (no LN) 12641 (4340, 20941) 12317 (7298, 17336)
     State 1 (LN) 20829 (14666, 26992) 22479 (14924, 30034)
     State 2 (LN) 47486 (30248, 64723) 27788 (19339, 36236)
     State 3 (LN) 154320 (100919, 207721) 39638 (27834, 51441)
     ESRD 242196 (182407, 301985) 240499 (180173, 300826)
10-year
     State 1 (no LN) 19987 (11061, 28913) 20499 (11681, 29318)
     State 2/3 (no LN) 25988 (12175, 39802) 25997 (15747, 36247)
     State 1 (LN) 47524 (33158, 61891) 50997 (34654, 67340)
     State 2 (LN) 111326 (76466, 146185) 61030 (42667, 79394)
     State 3 (LN) 310579 (217631, 403528) 84040 (59619, 108461)
     ESRD 451406 (339977, 562835) 448336 (335942, 560730)
eGFR = estimated glomerular filtration rate; ePrU = estimated proteinuria; ESRD = end-stage renal disease; LN = lupus nephritis; CDN = 
Canadian
*
eGFR: state 1 > 60 mL/min, state 2 30 – 60 mL/min, state 3 < 30 mL/min
ePrU: state 1 < 0.25 g/d, state 2 0.25 – 3.0 g/d, state 3 > 3.0 g/d
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